H. Lundbeck AS (OCSE:HLUN B) Stock Based Compensation : kr0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Stock Based Compensation?

H. Lundbeck AS's Stock Based Compensation for the three months ended in Mar. 2025 was kr0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was kr0 Mil.

H. Lundbeck AS Stock Based Compensation Historical Data

The historical data trend for H. Lundbeck AS's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Stock Based Compensation Chart

H. Lundbeck AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

H. Lundbeck AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Stock Based Compensation	Get a 7-Day Free Trial															-	-	-	-	-

H. Lundbeck AS Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0 Mil.

H. Lundbeck AS Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN B) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

HLBBF:USA HLUBF:USA HLUNBc:UK 0ABR:UK 0ND5:UK HLUN A:Denmark LDBB:Germany LUNB:Austria LUNA:Austria

Address

Ottiliavej 9, Valby, DNK, 2500

Website

https://www.lundbeck.com

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines